- Home
- RCEL vs OABI Comparison
RCEL vs OABI Comparison
Compare RCEL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- OABI
- Stock Information
- Founded
- RCEL N/A
- OABI 2012
- Country
- RCEL United States
- OABI United States
- Employees
- RCEL N/A
- OABI N/A
- Industry
- RCEL Medical/Dental Instruments
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- OABI Health Care
- Exchange
- RCEL Nasdaq
- OABI Nasdaq
- Market Cap
- RCEL 161.5M
- OABI 198.2M
- IPO Year
- RCEL N/A
- OABI N/A
- Fundamental
- Price
- RCEL $5.32
- OABI $1.74
- Analyst Decision
- RCEL Strong Buy
- OABI Strong Buy
- Analyst Count
- RCEL 4
- OABI 3
- Target Price
- RCEL $16.50
- OABI $7.00
- AVG Volume (30 Days)
- RCEL 326.4K
- OABI 1.1M
- Earning Date
- RCEL 08-07-2025
- OABI 08-07-2025
- Dividend Yield
- RCEL N/A
- OABI N/A
- EPS Growth
- RCEL N/A
- OABI N/A
- EPS
- RCEL N/A
- OABI N/A
- Revenue
- RCEL $71,661,000.00
- OABI $26,744,000.00
- Revenue This Year
- RCEL $57.16
- OABI N/A
- Revenue Next Year
- RCEL $36.69
- OABI $45.65
- P/E Ratio
- RCEL N/A
- OABI N/A
- Revenue Growth
- RCEL 41.35
- OABI 27.07
- 52 Week Low
- RCEL $4.71
- OABI $1.22
- 52 Week High
- RCEL $14.16
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- RCEL 39.85
- OABI 57.18
- Support Level
- RCEL $4.71
- OABI $1.55
- Resistance Level
- RCEL $5.55
- OABI $1.76
- Average True Range (ATR)
- RCEL 0.29
- OABI 0.10
- MACD
- RCEL 0.08
- OABI 0.02
- Stochastic Oscillator
- RCEL 41.03
- OABI 69.09
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.